The UK’s drugs regulator—the MHRA—has approved the Alzheimer’s drug donanemab, but it won’t be available on the NHS.
This article was originally published on MedicalXpress.com
Alzheimer’s drug approved in the UK, but it won’t be available on the NHS—here’s why
You may also be interested in:
The Latest
Why stress-related illness is so hard to diagnose, and how a patient-centred playful approach can help
For at least three decades, researchers have gathered evidence that chronic stress puts pressure on the body to constantly adjust itself to restore physiological stability. This process is known as allostatic load and it creates a cascade […]
The Latest
PetVet Dx Revolutionizes Wildlife Conservation with AI and Molecular Diagnostics to Combat Incurable CWD in Deer and Elk
Chronic wasting disease (CWD), a devastating prion illness that affects North American cervids like deer and elk, poses a grave threat to their well-being and conservation efforts. Furthermore, it presents a potential risk of human […]
The Latest
Why you should stop buying vitamins and get more sleep instead
Almost half of all Canadians regularly take at least one nutritional supplement such as vitamins, minerals, fibre supplements, antacids and fish oils. Many of these individuals are healthy and hoping to improve general well-being or prevent chronic […]
Read More:
-
A new paper in the journal Child Development shows how some aspects of family interaction among Indigenous people in Guatemala have fundamentally shifted with rapid [...]
-
As teens continue to spend more time on screens and social media, a new study finds that among 11-12-year-olds, excessive time online is associated with [...]
-
Can artificial intelligence-powered tools help enrich child development and learning?This article was originally published on MedicalXpress.com
